NAPROXEN SODIUM (naproxen sodium) by Humanwell Pharmaceutical is analgesic, anti-inflammatory, and antipyretic properties. First approved in 2006.
Drug data last refreshed 11h ago · AI intelligence enriched 6d ago
Naproxen sodium is an oral NSAID capsule approved in 2006 that provides analgesic, anti-inflammatory, and antipyretic effects by inhibiting COX-1 and COX-2 enzymes and reducing prostaglandin synthesis. It is used for pain management and inflammation across multiple indications. The drug is a potent inhibitor of prostaglandin-mediated pain and inflammatory pathways in peripheral tissues.
Post-LOE positioning indicates mature product with likely stable or declining margins, suggesting smaller commercial teams focused on retention and cost management.
analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of naproxen, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Naproxen sodium is a potent inhibitor of prostaglandin synthesis in vitro . Naproxen…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Multiple-Dose Safety Study of Fixed Combination of Acetaminophen/Naproxen Sodium in Adolescents With Orthodontic Pain
A Study of Acetaminophen/Naproxen Sodium Fixed Combination Tablets in Adolescents 12 to <17 Years of Age With Pain
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy
A Study of an Acetaminophen/Naproxen Sodium Fixed Combination, Acetaminophen and Naproxen Sodium in Postoperative Dental Pain
A Study to Learn How Well a Single Dose of the Study Treatment Naproxen Sodium and Caffeine Combined in One Tablet (Fixed-dose Combination) Works to Relieve Pain After Dental Surgeries Compared to the Single Ingredients and to Placebo
Worked on NAPROXEN SODIUM at Humanwell Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring
Working on naproxen sodium offers limited growth trajectory given post-LOE status and imminent generic cliff in March 2026. Professionals should expect role consolidation, transition to adjacent OTC/consumer health portfolios, or reassignment to growth-stage products within 18 months.